

**Freedom of Information Request**

Ref: UHB 17-159 (158)

Date 18 April 2017



Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

- 1) **Within your health trust how many patients are currently [within the past 6 months] being treated with a chemotherapy agent [not including surgery/radiotherapy only];**

All Non-Small Cell Lung Cancer patients	<b>140</b> (inclusive of all drugs)
Patients with Non-Small Cell Lung Cancer (NSCLC) Stage IIIB**/IV** (Stage 3b/4)	<b>75</b> (inclusive of all drugs)

- 2) **Of the NSCLC patients, please state the number of patients currently [within the past 6 months] being treated with the following therapies;**

<b>Treatment</b>	<b>Number of Patients (inclusive of all stages)</b>
Afatinib (Giotrif)	**
Ceritinib (Zykadia)	**
Crizotinib (Xalkori)	5
Erlotinib (Tarceva)	5
Gefitinib (Iressa)	0
Nitendaninb + docetaxel	5
Nivolumab (Opdivo)	**
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin	59
Pembrolizumab (Keytruda)	**
Gemcitabine mono or in combination with carboplatin / cisplatin	34
Paclitaxel mono or in combination with carboplatin / cisplatin	0
Doxetaxel mono or in combination with carboplatin / cisplatin	6
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin	16

- 3) If your trust does not treat these cancers and you refer your patients to another trust, please state which trust?

Please see response below.

- 4) Within your health trust how many patients are currently [within the past 6 months] diagnosed with Urothelial cancer?

All Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients (TREATED or UNTREATED);	Zero
Metastatic* or locally advanced* Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients	Zero

Please note we do not provide a diagnostic service for Urological Cancers. All patients are diagnosed at other providers (mostly North Bristol NHS Trust) and are referred here for oncology treatments only.

- 5) Of these patients (metastatic/locally advanced UCC), please state the number of patients currently [within the past 6 months] being treated with the following therapies;

<u>Treatment</u>	<u>Number of Patients</u>
Cisplatinium single agent	-
Cisplatinium in combination with another agent	-
Carboplatinium single agent	-
Carboplatinium in combination with another agent	-
Any other chemo regimen without cisplatinium or carboplatinium	-

Not applicable – please see above response.

**NB:**

- TNM staging for metastatic Urothelial Cancer = Any T, any N, M1
- TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0
- TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0
- TNM staging for Stage IV NSCLC = Any T, any N, M1

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
University Hospitals Bristol NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

A large black rectangular redaction box covering the signature area.